Compare Oscar Health Inc (OSCR) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance

Oscar Health (OSCR) trades at $29.60, up 1.72% with mixed technical signals showing neutral overall momentum. The company reported strong Q1 2026 earnings beat but faces profitability challenges with negative margins. Revenue growth from $11.7B in 2025 to projected $13.3B in 2026 indicates expansion, while cash flow trends show operational improvement. Analyst consensus is divided with 27% buy ratings against a $24.67 price target below current levels.

The stock presents growth potential through revenue expansion and cash flow generation, but profitability concerns and negative ROE pose significant risks. Current valuation at 0.61 P/S suggests reasonable pricing for growth, though execution on margin improvement remains critical for sustained upside.

SPMO trades at $144.50, up 0.42% on the day, with a technical outlook leaning bearish based on moving averages despite neutral oscillators. The ETF has demonstrated strong momentum performance in 2026, with a 26% year-to-date return as of July 20, 2026 (247 Wallst). It maintains a concentrated, tech-heavy portfolio, heavily weighted toward AI beneficiaries, driving its outperformance versus the S&P 500.

Outlook remains positive for momentum-driven gains, supported by AI-fueled growth, but risks include high volatility and sensitivity to sector rotations. The upcoming $0.25 dividend in June 2026 provides additional shareholder return. Analyst sentiment is generally constructive, though the concentrated portfolio demands caution during market downturns.